Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7656541

Vena cava filter devices.

K A Ballew·J T Philbrick·D M Becker
View original source ↗Export metadata ↓

Abstract

Vena cava filters are effective in preventing pulmonary embolism (PE) in patients with deep vein thrombosis or PE who either have contraindications to anticoagulation or have sustained a PE despite adequate anticoagulation. Although vena cava filters are not without complications, clinically significant morbidity and mortality are low. The use of vena cava filters as primary prophylaxis or therapy for deep vein thrombosis and PE should await the results of controlled trials.

Explore related subjects

AnticoagulantsEquipment DesignForeign-Body MigrationHumansPulmonary EmbolismThrombophlebitisVena Cava FiltersJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K A Ballew, J T Philbrick, D M Becker. 1995. Vena cava filter devices.. https://pubmed.ncbi.nlm.nih.gov/7656541/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Low molecular weight heparins and heparinoids.

Several low molecular weight (LMW) heparin preparations, including dalteparin, enoxaparin and nadroparin, as well as the heparinoid danaparoid sodium, are approved for use in Australia. LMW heparins are replacing unfractionated heparin for the prevention and treatment of venous thromboembolism and the treatment of non-ST-segment-elevation acute coronary syndromes. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and predictable anticoagulant response (avoiding the need for dose adjustment or laboratory monitoring in most patients), and a low risk of heparin-induced thrombocytopenia and osteoporosis. Laboratory monitoring of LMW heparin therapy should be considered in newborns and children, patients with renal impairment, those who are pregnant, and those at the extremes of bodyweight (eg, < 40 kg or > 100 kg). LMW heparins should: be avoided or used with caution in patients undergoing neuraxial anaesthesia, owing to the potential for epidural haematoma formation; not be used (ie, are contraindicated) in patients with immune heparin-induced thrombocytopenia, as they may cross-react with anti-heparin antibodies. Conventional unfractionated heparin retains a role in the management of patients at high risk of bleeding, undergoing invasive procedures, and patients with renal failure owing to its shorter half-life, reversibility with protamine sulfate, and extrarenal metabolism. The heparinoid danaparoid sodium is effective for the treatment of heparin-induced thrombocytopenia.

Anticoagulants↗